BLEOCIP

Indications

• Hodgkin's lymphoma
• Non-Hodgkin lymphoma
• Germ cell tumors
• Testicular cancer

Dosage

Children: Refer to BNF for Children for specific dosing guidance based on the child's condition and weight.

Adults: The usual adult dose is 15-30 units (1 unit = 1 mg) given intravenously, with dosing adjusted based on response and toxicity. Maximum cumulative doses should not exceed 400 units.

Mechanism of action

Bleomycin works by binding to DNA, causing single and double-strand breaks through oxidative damage. This action interferes with DNA synthesis and function, ultimately leading to apoptosis in cancer cells.

Pharmacodynamics

Bleomycin has a unique mechanism of action that is particularly effective against rapidly dividing cells. It is noted for its ability to induce pulmonary toxicity, which is a significant consideration in its use.

Pharmacokinetics

Bleomycin is typically administered intravenously and has a variable half-life of about 2-6 hours. It is primarily excreted unchanged in urine. Its distribution is extensive, with a high volume of distribution, indicating significant tissue binding.

Contra-indications

• Acute pulmonary infection
• Significantly reduced lung function

Adverse effects

• Alopecia
• Stomatitis
• Thrombocytopenia
• Peripheral neuropathy
• Hypoglycaemia
• Fever
• Nausea
• Vomiting
• Headache
• Photosensitivity reaction
• Infection
• Electrolyte imbalance
• Neurotoxicity

Interactions

• Brentuximabvedotin: Severe (increases risk of pulmonary toxicity)
• Live vaccines: Unknown (increases risk of generalized infection, possibly life-threatening)

Precautions

• Caution in handling-irritant to tissues
• Close monitoring for neurological events is strongly recommended

Pregnancy

Avoid (teratogenicity reported).

Breast-feeding

Discontinue breast-feeding.

Storage

Store below 25°C. Protect from light.

Formulations

• Injection: 15 units/ml solution for injection
• Powder for injection: 1 mg vials

Dosage

Children: Refer to the specific medication's prescribing information for paediatric dosing instructions after reconstitution.

Adults: Refer to the specific medication's prescribing information for adult dosing instructions after reconstitution.

Mechanism of action

The mechanism of action of reconstituted medications depends on the active pharmaceutical ingredient (API) present in the formulation. Once reconstituted, the drug is typically intended to exert its effects through specific pathways, such as receptor binding, enzyme inhibition, or other pharmacological actions related to its therapeutic class.

Pharmacodynamics

Pharmacodynamics will vary based on the specific drug being reconstituted. Generally, the reconstituted medication will interact with biological targets in the body, leading to therapeutic effects. This could involve modulation of neurotransmitter systems, hormonal pathways, or immune responses, depending on the drug's intended use.

Pharmacokinetics

Pharmacokinetics of reconstituted medications are similarly dependent on the specific drug. After administration, the pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion may vary. Factors like the route of administration (e.g., intravenous, intramuscular), the solubility of the drug, and patient-specific factors (e.g., age, liver and kidney function) will influence the drug's overall pharmacokinetic profile.

Pregnancy

Consult a healthcare provider before use, as risks and benefits must be evaluated on a case-by-case basis.

Breast-feeding

Consult a healthcare provider before use, as the effects on breastfed infants are not fully understood.

Storage

Store in a cool, dry place away from light. Follow specific storage instructions provided with the product.

Indications

• Surgical procedures
• Injection of medications
• Preparation of sterile pharmaceutical products
• Management of open wounds
• Use in controlled environments such as hospitals and laboratories

Dosage

Children: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Adults: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Mechanism of action

Sterility itself does not have a mechanism of action as it is a state of cleanliness and does not interact with biological systems. However, the methods used to achieve sterility, such as heat or chemical agents, act by denaturing proteins, disrupting cellular structures, or damaging nucleic acids in microorganisms, leading to their inactivation or destruction.

Pharmacodynamics

The pharmacodynamics of sterile techniques primarily involves the prevention of microbial infection and contamination when administering medications. By ensuring that products are sterile, the risk of adverse effects related to infections is minimized. The effectiveness of sterilization methods can be influenced by factors such as temperature, duration of exposure, and the type of microorganisms present.

Pharmacokinetics

As sterility does not pertain to a specific drug, pharmacokinetics is not applicable. However, the pharmacokinetics of a drug will depend on its formulation, route of administration, and the presence of preservatives or stabilizers that may be used alongside sterile preparations.

Pregnancy

Sterile preparations are generally considered safe during pregnancy as they are used to provide hydration, nutrition, or medications in a controlled manner, but specific formulations should be assessed individually.

Breast-feeding

Sterile solutions used for hydration or nutritional support are typically safe during breastfeeding, but any specific additives or medications within the solutions should be evaluated for safety.

Storage

Sterile solutions should be stored in a cool, dry place, protected from light, and should be used before the expiration date. Once opened, they may have specific storage requirements based on the formulation.

Formulations

• Sterile saline solution
• Sterile water for injection
• Sterile dextrose solution
• Sterile electrolyte solutions

Mechanism of action

Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. As evident in _in vitro_ studies, the DNA-cleaving actions of bleomycin is dependent on oxygen and metal ions. It is believed that bleomycin chelates metal ions (primarily iron) producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA. Cytotoxic action of bleomycins results from their ability to cause fragmentation of DNA. Studies in vitro indicate that bleomycin causes accumulation of cells in the G2 phase of the cell cycle, and many of these cells display chromosomal aberrations, incl chromatid breaks, gaps, and fragments, as well as translocations. Bleomycin appears to cause scission of DNA by interacting with oxygen and iron(2+). In the presence of oxygen and a reducing agent, such as dithiothreitol, the metallobleomycin complex becomes activated and functions mechanistically as a ferrous oxidase, transferring electrons from iron(2) to molecular oxygen to produce activated species of oxygen. It has also been shown that metallobleomycin complexes can be activated by reaction with the flavin enzyme, NADPH-cytochrome p450 reductase. Bleomycin binds to DNA through its amino terminal peptide, and the activated complex generates free radicals that are responsible for scission of the DNA chain. Bleomycin is an antineoplastic antibiotic. The drug is active against gram-positive and gram-negative bacteria and fungi, but its cytotoxicity precludes its use as an anti-infective agent. The precise mechanism(s) of action of bleomycin is not fully known. Several studies in Escherichia coli and HeLa cells suggest that the drug inhibits the incorporation of thymidine into DNA. In these in vitro studies, DNA synthesis was inhibited to a greater extent than was RNA or protein synthesis. Bleomycin also appears to labilize the DNA structure, resulting in scission of both single- and double-stranded DNA. The drug has no immunosuppressive activity in mice. Bleomycin is classed as an antibiotic but is not used as an antimicrobial agent. Although bleomycin is effective against both cycling and non-cycling cells, it seems to be most effective in the G2 phase of cell division. Its exact mechanism of antineoplastic action is unknown but may involve binding to DNA, inducing lability of the DNA structure, and reduced synthesis of DNA, and to a lesser extent RNA and ptoteins. When administered into the pleural cavity in the treatment of malignant pleural effusion, /bleomycin/ acts as a sclerosing agent.

Pharmacodynamics

Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown <i>in vitro</i> to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).